A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders

Inclusion Criteria: Subjects with PD: * Male or female subjects ≥ 40 and ≤ 80 years of age, at time of informed consent. * Diagnosed with Parkinson's Disease, as defined by the United Kingdom Parkinson Disease Brain Bank criteria, associated with REM sleep behavior disorder (PD) * Modified Hoehn \& Yahr ≥ stage 1 and ≤ stage 3 during "On" period as documented in the 3 months prior to Screening or completed at Screening. * Montreal Cognitive Assessment (MoCA) score ≥ 18 and ≤ 28. Subjects with MCI: * Male or female subjects ≥ 50 and ≤ 80 years of age, at time of informed consent. * Meet the criteria for amnestic Mild Cognitive Impairment (MCI) as per the National Institute on Aging-Alzheimer's Association core clinical criteria. * Montreal Cognitive Assessment (MoCA) score ≥ 18 and ≤ 26. * No dementia according to the International Classifications of Diseases (ICD)-10 and Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV. * Memory complaint reported by the subject or his/her partner, family member or caregiver. * Score of greater than or equal to one standard deviation below age and educational norms in the Digit Symbol Substitution Test (DSST) during Screening. * Cognitive decline not primarily caused by vascular, traumatic, or medical problems. Subjects with Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD): * Male or female subjects ≥ 50 and ≤ 80 years of age, at time of informed consent. * Diagnosis of dementia associated with Dementi…